CellaVision

CellaVision reported Q1 2026 net sales of SEK 166m, a 14.6% decline year-on-year, driven by inventory normalization in the EMEA region (-32%). The EBITDA margin was 24% and the company generated positive cash flow despite the sales drop. The stock fell 18.02% premarket to around SEK 126 and is trading near its 52-week low. CellaVision remains optimistic long term due to R&D investments and new product launches, but expects continued short-term headwinds from EMEA inventory levels and currency effects. » More on de.investing.com

CellaVision recorded net sales of SEK 197 million in the fourth quarter of 2025 (+5.6% year‑on‑year) and organic growth of 12.2%. EBITDA was SEK 65 million (33% margin) and the stock rose 11.43% in pre‑market trading. The company received CE marking for a new bone marrow application and plans to launch it in Europe in H2 2026, and to expand with methanol‑free staining reagents in the US. Further investments in research and development and partnerships to expand the market are planned. » More on de.investing.com

CellaVision reported revenue of CHF 176m for Q3 2025, missing the CHF 180.93m forecast, after which the share price fell 10.23% to 158. Organic revenue growth, adjusted, was 2.6%; at the same time EBITDA (CHF 50m, margin 28%) and gross margin (69%) improved. Higher R&D spending and increased operating costs weigh on results in the short term. Management emphasizes its focus on innovation and expects CE approval for a bone marrow application in early 2026 and a reagent rollout in the US in mid-2026. » More on de.investing.com

CellaVision recorded organic growth of 7.6% in the second quarter of 2025, despite currency headwinds and mixed regional performance. The company maintained a strong EBITDA margin of 31% and continued to invest heavily in research and development, with particularly strong growth in the APAC region. CFO Magnus Blixt announced his resignation, and the launch of new products is planned for early 2026. » More on de.investing.com